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Summary
The Epstein-Barr Virus(EBV) causes infectious mononucleosis, and has been strongly associated
with certain human cancers. The virus is thought to exclusively bind to B lymphocytes and
epithelial cells via receptors (CR2/CD21) that also interact with fragments of the third component
of complement (C3). Recent evidence, however, has challenged this belief. We have used two-
color immunofluorescence analysis usingbiotin-conjugated EBV and streptavidin-phycoerythrin
along with fluorescein-conjugated antiT cell antibodies and demonstrated that CD1-positive,
CD3-dull (immature) human thymocytes express functional EBV receptors. In four replicate
experiments, the binding of EBV to thymocytes ranged between 8 and 18%. This interaction
is specific as evidenced by inhibition with nonconjugated virus, anti-CR2 antibodies, aggregated
C3, and an antibody to the gp350 viral glycoprotein that the virus uses to bind to CR2. EBV
can infect the thymocytes as evaluated by the presence of episomal EBVDNA in thymocytes
that had been incubated with the virus as short as 12 days or as long as 6 weeks. Episomal DNA
analysis was performed by Southern blotting with a EBVDNA probe that hybridizes to the
first internal reiteration of the viral DNA. The presence of the EBV genome is also supported
by the detection of EBV nuclear antigen 1 in infected thymocytes, assessed by Western blotting
with EBVimmune sera. The EBV infection is specific as determined by blocking experiments
using anti-CR2 and anti-gp350 antibodies. Finally, virus infection of thymocytes can act
synergistically alongwith interleukin 2 and induce a lymphokine-dependent cellular proliferation.
In view of previously reported cases of EBVpositive human T cell lymphomas, the possibility
is raised that EBV may be involved in cancers of T lymphocytes that have not been previously
appreciated.
T
he EBV is the causative agent of infectious mononucle-
osis, and is associated with certain human neoplasias (1).
EBV is thought to display exclusive tropism for B lympho-
cytes (2-7), follicular dendritic cells of tonsils and lymph nodes
(8), and pharyngeal (9) and cervical (10) epithelia. The virus
targets these cellsvia specific surface receptors which are also
reactive with the C3d fragment of the third component of
complement (EBV/C3d receptors/CR2/CD21) (11-13).
Reports from several laboratories, including ours, have
provided evidence that challenges the exclusive B lympho-
cyte/epithelial cell tropism ofEBV In an earlyreport, Menezes
et al. (14) demonstrated the binding ofEBV to the lympho-
blastoid T cell line Molt 4. Fingeroth et al. (15) have purified
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and have performed limited NH2-terminal sequencing of a
CR2 protein found on the human leukemic T cell line HPB.
In own laboratory, we have demonstrated the reactivity of
normal human thymocytes with anti-CR2 mAbs and have
shown that these antibodies can immunoprecipitate a pro-
tein from thymocyte lysates that has the expected size (145
kD) for CR2 (16). Of particular interest are recent reports
describing the cases of patients with EBV genome-positive
T cell lymphomas (17-20), thus, suggesting that EBV could
be involved in cancers of T cells not previously appreciated.
In this report we describe the specific binding of EBV to
a subpopulation of phenotypically immature human thymo-
cytes and provide evidence indicating that the virus can in-
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antigen (EBNA)t. In addition, EBV can act synergistically
along with 11,2 to induce thymocyte proliferation in a lym-
phokine dose-dependent manner.
Materials and Methods
Cells, Antibodies, and OtherReagents.
￿
Human thymocytes were
obtained from patients (up to 4 y of age) undergoing corrective
cardiac surgery. Raji cells(CCL 86) were obtained from theAmer-
ican Type Culture Collection (Rockville, MD). The B95-8 mar-
mosetleukocyteline (CRL 1612)wasalso obtained from the same
source. Both cell lines were cultured at 37°C in a humidified at-
mosphere of 5% C02-air in RPMI 1640 (Mediatech, Washington,
DC) that was supplemented with 10% FCS (Hyclone Laborato-
ries, Logan, UT) and antibiotics (Gibco Laboratories, Grand Is-
land, NY). The cell concentration was adjusted to 2 x 105
cells/ml every 3-4 d. The cultures were free of mycoplasma.
The hybridomas producing anti-CR2 antibody HB5 (HB 135)
and anti-gp350 antibody 72A1 (HB 168) were obtained from the
American Type Culture Collection. They were carried in culture
as described above and used as culture supernatants. Purified anti-
bodies OKB7 andOKT6 were purchasedfrom OrthoPharmaceu-
ticals (Raritan, NJ). Purified antibodies Leu-12 and Leu-4 directly
conjugated to fluorescein were purchasedfrom Becton Dickinson
& Co. (Mountain View, CA). Goat anti-mouse and goat anti-
human IgGwere obtained from Jackson Immunoresearch Labora-
tories, Inc. (Avondale, PA); streptavidin-conjugated phycoerythrin
(strep-PE) was purchasedfrom Biomeda Corp. (Foster City, CA).
I'll-protein A (sp act 43 pCi/lAg) was from ICN Biochemicals,
Inc. (Irvine, CA). Moloney-murine leukemia virusreverse transcrip-
tase was from GibcoBethesda Research Laboratories (Gaithersburg,
MD). Oligonucleotides were synthesized in ourownfacility using
a synthesizer from Applied Biosystems (Foster City, CA).
EBVPurification and Biotin Conjugation.
￿
TheEBV used in these
experiments was purified from culture supernatants of the EBV
producing B95-8 cells. 2 liters of B95-8 cells, seeded at 2 x 105
cells/ml, were grownfor 14 din RPMI 1640 containing 10% FCS
and 5 ng/ml PMA (Sigma Chemical Co., St. Louis, MO). Cells
and cell debris were then removed by centrifugation (1,500 g, 30
min, 4°C), the supernatant was filtered through a 0.8-/Am filter
and centrifuged (15,000 g, 120 min, 4°C) to pellet the virus. The
pellet wasresuspended in TNB buffer (0.01 M Tris, 0.15 M NaCl,
0.1 mg/ml Bacitracin, pH 7.3) and layered onto a discontinuous
dextran T10 gradient containing equal volumes of 5, 10, 15, and
30% (wt/vol) dextran in TNB buffer. Thegradient was then cen-
trifuged (76,000g, 60 min, 4°C) in an SW 41 Ti rotor (Beckman
Instruments, Inc., Palo Alto, CA). The virus band was removed
from the 15/30% interface anddialyzed against TNB buffer. Final
volume of virus was 2 ml, resulting in a 1,000-fold concentration
ofthe original culture volume. Conjugation of biotin to EBV was
performedby addition ofbiotin-N-hydroxy-succinimide ester(Cal-
biochem-Behring, Corp., San Diego, CA) to 500 ml of purified
EBV in 0.1 M NaPO4, 150 mM NaCl buffer (PBS), pH 7.54, to
a final concentration of 2 mg/ml. This solution was allowed to
incubate at room temperature for 2 h and was then layered onto
a discontinuous dextran T10 gradient as described above. Biotin-
conjugated virus (bio-EBV) was isolated from the 15/30% inter-
' Abbreviations used in this paper. bio-EBV, biotin-conjugated Epstein Barr
Virus;EBNA, EBVnuclearantigen 1;SCR, shortconsensus repeat; strep-
PE, streptavidin-conjugated phycoerythrin.
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face, dialyzed against TNBbuffer, andtitrated on Raji cellsby im-
munofluorescence.
EBV DNA Probe. The EBV DNA probe pDK14 was the
generous gift of Dr. E. Kieff(Harvard University, Boston, MA);
it hybridizes to the long internal reiteration, IR1, of EBV DNA
(21). This plasmidthat contains BamHI fragments of EBV (B95-8)
DNA cloned into the BamHI site of pBR322 was propagated in
theJM109 strain ofEscherichia coli. Plasmidisolation, purification,
andnick translation were carried out by standard techniques (22).
Ttvo-color Immunofluorescence Analysis.
￿
The analysis was per-
formed as previously described (16). Determination ofEBVbinding
was performed by incubating 106 cells with bio-EBV, in a final
volume of 50 IA1, in V-bottomedmicrotiter plate wells(Costar, Cam-
bridge, MA) for 30 min. Cells were then washed with PBS, pH
7.3, and incubated with strep-PE in a 1:10 final dilution for an
additional 30 min. Cells were washed twice in L15 medium (2%
FCS),fixedin 1% paraformaldehyde, andanalyzed in aflow cytom-
eter (Ortho Cytofluorograph; Ortho Pharmaceuticals) . Antibody
staining wasperformedin a similarfashion with saturating amounts
of fluorescein-conjugated antibodies either alone or in costaining
experiments with EBV In selected experiments, blocking of EBV
bindingwastested by preincubating thymocytes with nonconjugated
anti-CR2 antibodies or with aggregated C3. Thelatter was purified
and aggregated as previously described (23, 24).
Polymerase Chain Reaction.
￿
The PCR was performed by the
method ofSaiki et al. (25) as modified by Witsell and Schook (26)
usingacommercially availablekit(Cetus Corp., Emeryville, CA).
All reactions were performedin 1.5-ml microcentrifuge tubes. The
RNA from thymocytes or a B cell line GY) was isolated by the
guanidinium thiocyanate method exactly as described by Witsell
and Schook (26) and reversely transcribed by addition of random
hexamers, deoxynucleotides, and Moloney-murine leukemia virus
reverse transcriptase (26). The reaction proceeded for 1 h at 42°C
andwas terminatedby heating at 90°Cfor 10 min. Apair ofspecific
primers that amplify a 279-bp segment of the CD19 gene were
constructed and used for amplification. The sequence of these
primersis 5'-TCACCGTGGCAACCTGACCAT3' (extends down-
stream) and 5'-GAGAGACAGCACGTT3' (extends upstream). As
a control, we also used a pair of primers that amplify 800 by of
an unrelated gene (GTP-binding protein stimulatory a subunit).
The PCR was performed in a thermocycler (Ericomp Inc., San
Diego, CA) exactlyas describedby Witsell andSchook (26) without,
however, the addition of an internal primer. The detection of the
PCRproducts was performed by agarose gel (2%) electrophoresis
and by staining with ethidium bromide.
EBV Infection and Episomal DNA Analysis.
￿
Total thymocytes
or thymocytes purified by SRBC rosetting, as previously described
(27), were incubated at a concentration of 2 x 106 cells per ml
in culture flasks (#3151; Costar) with B95-8 culture supernatants
(1:10dilution) forvarious days. Cellswere harvested, episomalDNA
was extracted, as previously described (28), and subjected to Bam
HI (Promega Biotec,Madison, WI) digestion. 10 hg of thedigested
DNA, corresponding to 2-3 x 106 Raji cells or 6-7 x 106
thymocytes, wasanalyzedby Southern blotting (29) with theprobe
pDK14that specifically recognizes a 3-kb fragment corresponding
to the first internal reiteration of theEBV genome (21). Episomal
DNAisolated from theEBVtransformed Raji Bcellline wastreated
in an identicalfashion andused as apositivecontrol.Episomal DNA
from thymocytes that had not been exposed to EBVwas also ana-
lyzed as a negative control.
Detection ofEBNA-1.
￿
Detection was performedby Westernblot-
ting analysis as previously described (30). Briefly, EBVinfected
thymocyte lysates or noninfected controls were incubatedin RPMI1640 with 10% FCS for 7 d . After harvesting and washing, cells
were resuspended at 108 per ml of sample buffer (40 mM Tris-
HCI, pH 7.4, 15% glycerol, 2% SDS, 5% 2-ME 1 ug/ml pep-
statin A, 2mM PMSF, and 0.02% bromophenol blue), sonicated
(60 s), and boiled . Debris was removed by centrifugation and an
amount of lysate corresponding to 5 x 101 cell equivalents was
subjected to electrophoresis on preparative10%polyacrylamide SDS
slab gels andthen electrophoretically transferred toNYTRAN filters
(Schleicher and Schuell, Inc., Keene, NH). The filters were satu-
rated with 1% powdered milk-0.1% gelatin solution inBBS (0.05
Msodium borate-0.14M NaCl, pH 8.3) and cut into 3-mm strips .
The strips were probed with a previously characterized EBNA-1-
specific serum that was collected from a donor with a past EBV
infection (30) . The strips were also probed with two differentEBV
negative sera, which were provided to us byDr. R. Smith (Ortho
Pharmaceutical, San Diego, CA). These latter sera are heterophile
negative (Monospot; Ortho Pharmaceutical), negative in the
Monolert assay (Ortho Pharmaceutical) for both IgG and IgM an-
tibodies, and negative in Western blots using Wi-L2 andphorbol
ester induced B95-8 cell extracts (31) . They are also negative in
immunofluorescence assays for viral capsid antigen IgG and IgM
antibodies and early antigen and in anticomplement immunofluores-
cence assays for EBNA-1 (Granbio, Inc., Temecula, CA) . The sera
were diluted in 1% powdered milk, 0.1% gelatin-BBS, and incu-
bation was carried out for 1 h at room temperature (RT) . After
washing in BBS, the protein bandswere visualized by reacting with
goat anti-human IgG for 1 h; RT, followed by incubation with
12sí-protein A (1 h ; RT) and autoradiography. Additional controls
included neutralization of the anti-EBNA antiserum with a syn-
thetic peptide (p62) that represents the glycine-alanine repeating
major epitope of EBNA-1 (30) . This wasperformedby incubating
the sera overnight at 4°C with 10 ug/ml of peptide in 1% pow-
dered milk, 0.1% gelatin-BBS.
Measurement ofProliferative Response.
￿
Thymocytes, purified by
SRBC rosetting, as previously described (27), were incubated (37°C,
5% COs-air) at 106 cells per microtiter tray well (#3596 ; Costar)
for 2 d in the presence ofEBV or without any additions . Subse-
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quently, various concentrations of rIlJ2 were added, or no addi-
tions were made as a control, and incubation was continued for
5 d. Cellular proliferation was assessed as previously reported (32)
by the incorporation of [3H]-thymidine. The delay of rIL2 addi-
tion was necessitated due to the fact that human thymocytes
proliferate in response to íL2, and this reaction is dampened iflym-
phokine addition is delayed by 2d. In other experiments both virus
andíL2 additions were delayed for2d . TheEBVused in the prolifer-
ation experiments was isolated from B95-8 tissue culture superna-
tants by centrifugation (15,000,g, 120 min, 4°C) and washing in
order to remove PMA. The final virus concentration used in the
cultures represented a 1/4 dilution ofthe original culture superna-
tant . Human rIL2 produced inE . coli (33) wasgenerously provided
by the Cetus Corp. IL-2 Lot LP315 was shownby the supplier to
be 98% pure by SDS-PAGE and contained <0.01 ng endotoxin
per mg íL2 . 1 U of 11,2 activity is the amount producing half-
maximal growth of an IIL2-dependent cell line.
Results
EBV Binds Specifically to Thymocytes. .
￿
Our previous ob-
servations on human thymocyte reactivity with anti-CR2
mAbs, along with the findings of others discussed above,
prompted us to examine the binding and biological effects
that EBV may have on thymocytes . To this end, thymocytes
were incubated with purified bio-EBV and viral bindingwas
visualized in a flow cytometer after staining with strep-PE .
It can be seen from the data displayed in Fig . 1, b andfthat
a significant portion of thymocytes boundEBV(positive cells
are enclosed in the rectangle) .
The specificity ofEBVbinding was tested by blocking with
anti-CR2 mAbs (HB-5 and OKB7) and by the third com-
plement component C3, since these modalities have been
shown to block the binding ofEBV to B cells (11-13, 34) .
Pretreatment ofthymocytes with HB-5 plus goat anti-mouse
Figure 1 .
￿
EBV binding to human
thymocytes and blocking by anti-
CR2 antibodies and by aggregated
C3 . Thymocytes were incubated
with predetermined optimal amounts
of bio-EBV without pretreatment
(b and J), or after preincubation
with 100 Ag/ml antibody HB-5 and
goat anti-mouse immunoglobulin
(GciM) (c), or 10,ug/ml OKB7 (d),
or 50 gg/ml aggregated C3 (agg-
C3) (g) . Binding was visualized in
a flow cytometerby the additionof
strep-PE . The results are displayed
as fluorescence (vertical axis) versus
forward scatter (horizontal axis) in
logarithmic scales . Nonspecific fluor-
escence was determinedby treating
cells only with strep-PE (a and e) .
The rectangles demarcate the posi-
tive cell area .Ig or OKB7 alone practically eliminated EBV binding (Fig.
1, c and d) . Pretreatment with aggregated C3 also caused
a significant reduction in EBV binding (Fig. 1 g) . Aggregated
C3 was used in this experiment because of the low affinity
of CR2 for monomeric ligand (35) .
There are two experiments displayed in Fig . 1 (one in the
upper panels, and one in the lower panels) each performed
in duplicate with cells from different donors . The percentage
EBVreactive cells, in the four experiments, ranged between
8 and 18% . The percentage ofEBVreactive cells for the specific
experiments displayed in Fig. 1 is 9% (population enclosed
in rectangle, b) and 8% (population enclosed in rectangle,
J), respectively. After HB-5+GcM Ig treatment EBV binding
was reduced to 0.9% (Fig . 1 c), after OKB7 treatment to
0.4% (Fig. 1 d), and after aggregated-C3 treatment to 4%
Figure 2 .
￿
Characterization of the thymocyte subpopulation that binds
EBV Thymocytes were analyzed by two-color staining as follows : (a) an-
tibody Leu-12 (green ; anti-B cell specific), (b) bio-EBV (red) plus antibody
Leu-12 (green), (c) antibody OKT6 (green; anti-immature thymocyte
specific), (d) antibody Leu-4 (green; antiT cell/mature thymoryte specific),
(e) bio-EBV (red) plus antibody OKT6 (green), (l) bio-EBV (red) plus
antibody leu4 (green) . Binding ofbio-EBV was visualized by the addition
of strep-PE (red) . The antibodies were directly fluorescein conjugated
(green) . Groups that did not receive bio-EBV were treated with strep-PE
as control while the negative control for the antibodies was the isotype-
matched (IgGl) antibody Leu-12 (B cell marker) . All reagents were used
at predetermined saturating concentrations . The results are representative
of two replicate experiments with cells from different donors . Cells were
analyzed in a flow cytometer (Ortho Diagnostic Systems) and results are
displayed as dot plots of red fluorescence (PE) versus green fluorescence
(fluorescein) in logarithmic scales. The rectangle demarcates the double-
positive cell area .
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(Fig. 1 g) . Inhibition of viral binding with anti-CR2 anti-
bodies in the other replicate experiments ranged between 90
and 96% and with aggregated C3 between 45 and 50% .
We further confirmed the specificity ofEBV binding by
preincubating thymorytes with nonconjugated virus or by
pretreatment of bio-EBV with mAb 72A1 which reacts with
gp350 (36), the EBV envelope glycoprotein that the virus
uses to bind to its receptor (36, 37) . In both cases binding
of biotinylated virus was significantly inhibited (data not
shown) .
TheEBVReactivehpulationHas an ImmaturePhenotype
￿
To
identify the particular subpopulation ofthymocytes that binds
the virus, we performed two-color immunofluorescence anal-
ysis using bio-EBV/strep-PE (red fluorescence) and directly
fluorescein-conjugated antibody OKT6 (anti-CD1 ; immature
thymocytes ; reference 38) or antibody Leu-4 (anti-CD3 ; ma-
ture thymocytes ; reference 39) (green fluorescence) . The results
of such an experiment, shown in Fig . 2, indicate that practi-
cally all ofthe EBVreactive thymocytes (11% in the displayed
experiment) also reacted with the anti-CD1 marker (Fig . 2
e, cells enclosed in rectangle) . Staining with both EBV and
antibody Leu-4 revealed two distinct populations, one con-
taining EBVreactive cells that were dull forCD3 expression,
while the other population was bright for CD3 and lacked
EBV binding (Fig. 2f) . This indicates that the EBVreactive
thymoryte subpopulation has an immature phenotype .
EBV Infects Thymocytes and Induces the Expression ofEBNA-1 .
We next examined the ability ofEBV to infect human thymo-
cytes . To this end, thymorytes were incubated with virus-
containing culture supernatants (1395-8 marmoset cell line)
for 5 and 12 d and isolated episomal DNA was tested for
hybridization with an EBV DNA probe (pDK14) which hy-
bridizes to the long internal reiteration, IR1, ofEBVDNA
(21) . Autoradiography of the so-obtained Southern blots re-
vealed a band of ti3 kb in size in the 12-d cultures, but not
in the 5-d cultures (Fig . 3 A) . The size of the signal is consis-
tent with the reported size of the EBV DNA fragment to
which thepDK14 probe hybridizes (21) . The 3-kb signal was
not seen in control thymocyte cultures that were not infected
with virus (Fig. 3 A) . Similar analysis of an EBVpositive
B lymphoblastoid cell line, Raji, revealed a signal of the same
size (Fig. 3 A) .
The infection ofthymorytes was inhibited by pretreatment
of the cells with anti-CR2 receptor antibody HB-5 plus goat
anti-mouse Ig or by preneutralization of the virus with the
anti-gp350 antibody 72A1, thus, demonstrating the specificity
of the infection (Fig. 3 C) . In the results displayed in Fig .
3, the variability in the strength of the signals probably reflects
differences in the specific activity of the radiolabeled DNA
probe.
We further tested for the production of EBVrelated pro-
teins in virally infected thymocytes . Cells were incubated with
EBV ormedium for 7 d, cell lysates were prepared, subjected
to electrophoresis, and blotted. The blots were then probed
with a previously characterized EBVpositive antiserum con-
taining reactivity against the glycine-alanine repeating major
epitope ofEBNA-1 or with EBVnegative sera (30) . The data
in Fig. 4 A (lane 2) indicate that a band of -70 kD was
Human Thymocytesrevealedby theEBVpositive serum in the virus-infected thymo-
cytes, but not in the noninfected control (Fig. 4 A, lane 1) .
Probing with two different EBVnegative sera did not reveal
a band (Fig. 4 A, lanes 3 and 4) . The size of the detected
band and the fact that the signal was revealed with EBV
positive, but not with EBVnegative, sera suggests that this
protein may represent EBNA1 (30) .
Additional evidence that the detected band represents
Figure 4 .
￿
Detection of EBNA-1 expression . Purified (SRBC-rosetted)
thymocytes, 106/ml, were incubated (37°C, 5% C02-air) for 7 d in flasks
containing B95-8 culture supernatants (final dilution 1:10) or medium as
control. Cells were washed and lysates prepared as described in Materials
and Methods . (A) Lysates of noninfected (lane 1) or EBVinfected (lanes
2-4) thymocytes were probed with EBVimmune (lanes 1 and 2; 1:500
dilution) or two different nonimmune (lanes 3 and 4 ; 1:500 dilution) sera .
(B) Lysates of EBVinfected thymocytes were probed with EBVimmune
serum (1:6,000 dilution) that had been preincubated with 10 ttg/ml of
p62 peptide (lane 2) or without it (lane 1) . Molecular mass markers used
were phosphorylase b (97.4 kD), bovine albumin (66 kD), egg albumin
(45 W), glyceraldehyde-3-phosphate dehydrogenase (37 kD) ; all wereob-
tained from Sigma Chemical Co. Results represent those of two replicate
experiments with thymorytes of different donors . Peptide neutralization
represents a single experiment.
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Figure 3 .
￿
Infection ofhuman thymocytes byEBV Southern
blottinganalysis with the EBVDNA probe pDK14 ofsamples
of episomal DNA (10 ug per lane) isolated from (A) EBV
infected (5 and 12 d) or noninfected thymocytes and from
Raji (EBVgenome positive) B cell lymphoblasts, (B) EBV
infected thymocytes that had been purified by SRBC roset-
ting before culturing with the virus, (C) thymocytes that had
been pre-treated with antibody HB5 plus goat anti-mouse
Ig (HB5/GceM) or not treated (medium only) and then in-
fected with EBV which hadbeen preincubated with anti-gp350
antibody (a-gp350) or not treated (medium only) . The posi-
tion of the3-kb marker was determined by analyzing BstEIl-
digested XDNA . The data presented in each panel represent
different experiments using specimens from separate donors.
EBNA1 was obtained by blocking serum reactivity with
a synthetic peptide, p62, representing the glycine-alanine
repeating portion of the protein . This peptide represents the
major epitope inhumans and it inhibits the binding of>90%
of the anti-EBNA-1 antibody in the serum used in these ex-
Figure 5 .
￿
Presence of EBV genome in long-term thymocyte cultures .
Purified (SRBC rosetted) thymocytes, 2 x 106/ml, were incubated (37°C,
5% COZ air) for 6 wk in flasks containing B95-8 culture supernatants
(final dilution 1:10) and rIL2 (32 U/ml) . Cells were maintained at 1-2
x 106 cells/ml by weekly feedings with fresh medium containing 10 U
ofIL2 per ml . Cells were harvested, washed, and episomalDNA was iso-
lated and analyzed by Southern blotting as described in Materials and
Methods . Results display two cultures using thymocytes from different
donors (thymocyte 1 and thymocyte 2) . For comparison, episomalDNA
isolated from the EBVpositive cell line Raji has been included . The posi-
tion of the 3-kb marker was determined by analyzing Bst Ell digested
DNA .periments (30) . Incubation of this serum with the peptide
blocks binding to the 70-kD antigen found in the infected
thymocytes (Fig. 4 B, compare lanes 1 and 2) . This experi-
ment was done at a higher serum dilution so the positive
signal is weaker than the one seen in Fig. 4 A (lane 2) .
In other studies,we assessed the stability of theEBVDNA
in infected thymocytes. In long-term cultures, we incubated
thymocytes with EBV in the presence of IL2 for a period
of 6 wk and then assessed the presence of EBV in the cells
by analyzing episomalDNA by Southern blotting as described
above. The data in Fig. 5 indicate that in two different thymo-
cyte culturesEBVDNA persisted during this period of time.
Evidence that the above observations represent infection
of thymocytes and not of another contaminating cell type
is supported by several observations. First, EBV binding is
associated with CD1 expression (see Fig. 2 e), which is a
specific marker of immature thymocytes (38) . Second, im-
munofluorescence staining and cytofluorographic analysis re-
vealed that the thymoryte populations consisted of99-100%
CD2-positive cells and did not contain any significant number
of cells (<I%) reactive with an anti-CD19 antibody (B cell
marker ; reference 40) either before or after incubation with
virus for 12 d . It is reasonable to expect that ifB cells were
contaminating our thymoryte population, we should had been
able to detect higher anti-CD19 reactivity after EBV infec-
tion . Third, repeat of the experiment displayed in Fig. 3 A
Figure 6 .
￿
Absence ofB cell specific messages from the thymoryte popu-
lation. Total RNA (5 t`g) from theJY B cell line (lanes 1 and 2) or SRBC-
rosetted thymocytes (lanes 3 and 4) was reversely transcribed and amplified
as described in Materials and Methods with specific primers that hybridize
to either the B cell-specific CD19 DNA (lanes 1 and 3) or with primers
that hybridize to theDNA coding for the ct subunit of the stimulatory
GTRbinding protein (lanes 2 and 4) which is expressed in both B cells
and thymocytes . The marker ladder was obtained by analyzing BstEII-
digested XDNA . The results are those obtained from a typical prepara-
tion of purified thymocytes .
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Figure 7 .
￿
Induction of thymoryte proliferation EBV Thymocytes, 106
per microtiter tray well, that had been purified bySRBC rosetting were
cultured in microtiter tray wells in the presence or absence of EBV for
2 d, then various concentrations of 11,2 were added andcultures incubated
for an additional 5 d . Delay of IL2 addition was necessitated to allow
a spontaneously IL2-responsive thymoryte population to become quies-
cent . proliferation was measured by the incorporation of (3H]thymidine .
Controls receiving EBV only are denoted by the closed circle and those
receiving medium only by the closed square. The results are displayed as
the averages of triplicate determinations (t SD) . The results arerepresen-
tative of three experiments using cells from different donors. In one of
the experiments, 0 .5 x 106 cells per well were used with identical results .
with highlypurified (SRBC-rosetted) thymocytesyielded iden-
tical results (Fig. 3 B) . Fourth, analysis of the RNA from
purified thymoryte population by PCR, using oligonucleo-
tide primers that amplify the B cell-specific marker CD19
(40), revealed no specific product in the thymocytes (Fig . 6,
lane 3), while the expected product of 279 by was amplified
in theB cell controlRNA (Fig. 6, lane 1) . Primers hybridizing
to a gene (ot subunit of the stimulatory GTP-binding pro-
tein), which is unrelated to CD19, amplified the expected
800-bp segment in both B cells (Fig. 6, lane 2) and thymo-
cytes (Fig. 6, lane 4) . Collectively, the above observations
indicate that the cells that interact with EBV are indeed
thymocytes.
EBVandIL2 Have a Synergistic Effect on Thymocyte Prolifer-
ation . We wished to ascertain the functional consequences,
if any, EBV may have on thymocytes. Addition of the virus
to purified thymocytes caused a small, but significant degree
of proliferation (Fig. 7) . Since we knew, from other studies
of ours (41), that thymocytes can respond to IL2, we tested
the ability of this lymphokine to act synergistically with the
virus. To minimize the spontaneous proliferative response that
thymocytes have with 11,2, we delayed the addition of the
lymphokine, since such a manipulation greatly reduces this
spontaneous response. Thus, thymocytes were cultured with
EBV for 2 d and then various concentrations of IL2 were
added . Controls included cultures that receivednoEBV during
the preincubation period. Under these experimental condi-
tions, it was observed that EBV and 11,2 act synergisticallyTable 1.
￿
Proliferation of THymocytes in Response to EBV
and IL-2
The experiment was performed in a fashion similar to the one displayed
in Fig. 7 with the exception that EBV was added either 2 d before IL-2
or along with IL-2 after the cells had been incubated in medium for 2 d.
The appropriate controls for each order of additions are also displayed.
The data displayed are from a single experiment using thymocytes from
a different donor than the ones used in Fig. 7.
in a lymphokine dose-dependent fashion to induce thymo-
cyte proliferation (Fig. 7). To determine the need for EBV
presence during the 2-d preincubation period, we cultured
thymocytes without EBV for 2 d followed by simultaneous
addition of virus and IL2. In these cultures no synergistic
proliferative effect was seen (Table 1) .
Discussion
In the present investigation, we provide evidence that in-
dicates that a subpopulation of immature human thymocytes
expresses EBV receptors. The virus binds specifically to these
cells, infects them, induces EBNA1 expression, and syner-
gistically with IIr2 causes their proliferation.
The binding ofEBV to thymocytes is specific. This is ascer-
tained by the inhibition ofviralbinding with anti-CR2 mAbs
and aggregated C3, manipulations known to specifically in-
hibit the binding ofEBV to B lymphocytes (11-13, 34). Fur-
thermore, EBV targets an immature thymocyte subpopula-
tion. This is evidenced by the fact that the virus binds to
cells that display the CD1 marker and are dull for CD3 ex-
pression, both of which are consistent with an immature
phenotype (38).
The nature of this thymocyte receptor is not well under-
stood. The CR2 expressed on B lymphocytes has been re-
cently cloned and characterized (42-44). It consists of 15 or
16 60-70 amino acid repeats called short consensus repeats
(SCRs) followed by a transmembrane and an intracytoplasmic
domain. Investigators have used truncated CR2 mutants that
bear serial deletions of their SCRs, or chimeric proteins con-
taining SCRs from both CR2 and CR1 in order to map the
epitopes that bind ligands such as C3 and EBV or mono-
clonal anti-CR2 antibodies (45, 46). It has been observed
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that theseligands bind to epitopes structured bydifferent SCRs
(45, 46). For instance, antibodies OKB7 and HB5 react with
epitopes that are formed by the first four SCRs, while anti-
body B2 reacts with an epitope shaped by SCRs 9-11 (45,
46). In view ofthe previously reported differential reactivity
of anti-CR2 antibodies with thymocytes (16), we propose
the possibility that the thymocyte UV -binding molecule may
represent an alternate form ofCR2. This couldbe manifested
by either a missing SCR or by the presence of a novel SCR.
This possibility is supported by information on a limited amino
acid sequence obtained from a CR2-like protein that was iso-
lated from a leukemic T cell line (15). This sequence is
significantly different from the sequence of CR2 on B lym-
phocytes (15) .
It is well established that EBV receptors on B cellsare iden-
ticalto C3d receptors (11-13). Several earlier reports by other
laboratories had described the presence of C3 binding pro-
teins on cells of the T lineage (47-52). In these studies, the
C3-reactive molecules were assessed by rosetting techniques
and no structural or functional characterizations were per-
formed. Thus, the nature and significance of these receptors
could not be fully determined. Menezes et al. (14), using roset-
ting techniques, and lateron Shapiro et al. (53), using radio-
active EBV, reported the presence of EBV receptors on the
T cell leukemia Molt 4. These reports claimed that although
the virus could bind to the cells, it failed to internalize and
thus, they proposed the possibility that this T cell EBVbinding
protein might be different than the CR2 found on B lym-
phocytes. In view of the data presented here, it is possible
that either the virus receptor on Molt 4 is different, due to
the leukemic state of the cells, or that EBV may bind to
different receptors that vary in their functional and/or struc-
tural properties. The latter possibility is supported by data
from our laboratory (J. Hedrick, D. Watry C. Speiser, P.
O'Donnell, J. Lambris, C. Tsoukas, manuscript submitted)
where a T cell leukemic line although capable ofbinding and
internalizing EBV, lacks expression of CR2 as assessed by
anti-CR2 antibodies and Northern blotting analysis. Recent
data from Sauvageau et al. (54) also support the contention
that EBV receptor heterogeneity may existby providing evi-
dence of the existence of such virus receptors on peripheral
CD8+ T cells of healthy individuals. It was noted that these
receptors do not react with the anti-CR2 antibody OKB7.
EBV can infect the thymocyte subpopulation it binds to
as evidenced by the presence of episomal EBVDNA in thymo-
cytes after 12 d in culture with the virus. Furthermore, the
fact that EBVDNA could be detected in thymocytes even
after 6 wk postinfection, indicates that the viral genome is
stable in these cells. Additional evidence of the stability of
EBV in thymocytes is the production of EBNA-1 which is
known to be necessary for EBV episome maintenance (55).
EBV acts synergistically with IL2 to induce a lymphokine-
dependent thymocyte proliferation. It is interesting that delayed
addition of EBV, afterthymocytes have been incubated quies-
cent for 2 d, eliminates this synergistic effect suggesting that
the thymocyte target population is short lived and infection
by EBV is probably necessary earlyafterthymocyteshave been
placed in culture. Although the exact biologic significance
Day 0
Additions
Day 2 [3H]Thymidine incorporation
cpm ± SD
Medium Medium 226 ± 155
Medium IL-2 11,254 ± 1,560
EBV Medium 608 ± 220
Medium EBV 141 ± 28
EBV IL-2 18,918 ± 540
Medium EBV+IL-2 9,260 ± 723ofthe thymocyte EBV receptor is not understoodat the present
time, the synergistic effect ofEBV and 111,2, and the selective
expression of the receptor on immature thymocytes, suggest
the possibility that this molecule may be involved in T cell
development. Several observations have indicated that CR2
on Blymphocytes may be involved in thedifferentiationand/or
activation ofthese cells (6, 7, 56-59). Finally, there exists the
potential that use of EBV and IIr2 may provide tools for
the in vitro expansion and maintenance of thymocytes and
the generation of clones for the study of human thymocyte
differentiation.
The recent reports ofEBV DNA-bearing T cell lymphomas
is particularly intriguing. In these studies, Kikuta et al. (17)
reported the case of a patient, who after clinical EBV infec-
tion, developed a Kawasaki-like disease with the interesting
characteristic of circulating T cells that carried EBV genome.
Jones et al. (18) described three different cases ofpatients with
T cell lymphomas that carried EBV genome who, similar
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